Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 9/20 | 0.44 |
| ▸ | SIRT5 | Q9NXA8 | 6/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.42 |
| ▸ | FURIN | P09958 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24477218 | 0.98 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3FURIN | |
| SCHEMBL25009079 | 0.98 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3FURIN | |
| SCHEMBL19708237 | 0.94 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3FURIN | |
| SCHEMBL20467806 | 0.94 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3FURIN | |
| SCHEMBL19046498 | 0.92 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3FURIN | |
| SCHEMBL17815409 | 0.92 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3FURIN | |
| SCHEMBL19503141 | 0.92 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3FURIN | |
| SCHEMBL17722938 | 0.92 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3FURIN | |
| SCHEMBL20864058 | 0.91 | SIRT2 (0.43) | SIRT2SIRT1SIRT5SIRT3FURIN | |
| SCHEMBL21008362 | 0.91 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3FURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161911-B2 | Anti-glyco-MUC1 antibodies and their uses | GO THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20190119400-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161911-B2 | Anti-glyco-MUC1 antibodies and their uses | MUC1, SIGLEC7, SIGLEC9 | SIRT2 3519/4885SIRT1 3972/4885SIRT5 2905/4885 |
| US-20190119400-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | MUC1, SIGLEC7, SIGLEC9 | SIRT2 3519/4885SIRT1 3972/4885SIRT5 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.